EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients

Francesca Bettelli, Daniela Vallerini, Ivana Lagreca iD, Patrizia Barozzi, Giovanni Riva, Vincenzo Nasillo, Ambra Paolini, Roberto D'Amico, Fabio Forghieri, Monica Morselli, Valeria Pioli, Andrea Gilioli und 20 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306728 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Francesca Bettelli und 31 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Modena, Modena, Italy. Hauptthemen laut MEDLINE: Enzyme-Linked Immunospot Assay. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, PNRR CN3 Terapia Genica-Spoke 2, Associazione Italiana Contro le Leucemie - Linfomi e Mieloma (AIL) - Sezione Luciano Pavarotti - Modena ONLUS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We investigated the performance of enzyme linked immunospot (ELISpot) assay for the diagnosis of invasive aspergillosis (IA) in high-risk patients with hematologic malignancies.

Methods

We prospectively enrolled two cohorts of patients undergoing intensive myelosuppressive or immunosuppressive treatments at high risk for IA. ELISpot was performed to detect Aspergillus -specific T cells producing Interleukin-10.

Results

In the discovery cohort, a derived cut-off of 40 spot forming cells (SFCs)/10 6 PBMCs has shown to correctly classify IA cases with a sensitivity and specificity of 89.5% and 88.6%, respectively. This cut-off is lowered to 25 SFC when considering the subset of possible IA patients, with sensitivity and specificity of 76% and 93%, respectively. The application of the 40 SFCs cut-off to the validation cohort resulted in a positivity rate of 83.3% in proven/probable cases and a negativity rate of 92.5% in possible/non-IA cases. Adopting the 25 SCFs cut-off, the assay resulted positive in 83.3% of proven/probable cases while it resulted negative in 66.7% of possible/non-IA cases.

Conclusions

ELISpot shows promises in the diagnosis of IA and the possibility to use two distinct cut-offs with similar diagnostic performances according to patients’ different pre-test probability of infection can widen its use in patients at risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme-Linked Immunospot AssayHumansMaleFemaleMiddle AgedAgedAdultProspective StudiesAspergillosisInterleukin-10Hematologic NeoplasmsSensitivity and SpecificityT-Lymphocytes

Substanzen

Interleukin-10

Autor:innen und Institutionen

  • Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Modena, Modena, Italy.
  • Diagnostic Hematology and Clinical Genomics, Department of Laboratory Medicine and Pathology, AUSL/AOU Modena, Modena, Italy.
  • Statistic Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Modena, Modena, Italy.
  • Hematology Division, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli - IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.
  • Department of Hematology, University Hospital UZ Leuven, Leuven, Belgium.
  • Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Bologna, IRCCS-AOU Policlinico Santorsola, Bologna, Italy.

ORCID-Profile: Ivana Lagreca, Livio Pagano, Enrico Tagliafico

Förderung

  • Gilead Sciences
  • PNRR CN3 Terapia Genica-Spoke 2
  • Associazione Italiana Contro le Leucemie - Linfomi e Mieloma (AIL) - Sezione Luciano Pavarotti - Modena ONLUS
  • fondazione IRIS CERAMICA GROUP
  • FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA
  • Regione Lombardia
  • Fondazione IRCCS Policlinico San Matteo
  • Fondazione Just Italia

Zitieren

APA

Bettelli, F., Vallerini, D., Lagreca, I., Barozzi, P., Riva, G., Nasillo, V., Paolini, A., D'Amico, R., Forghieri, F., Morselli, M., Pioli, V., Gilioli, A., Giusti, D., Messerotti, A., Bresciani, P., Cuoghi, A., Colaci, E., Marasca, R., Pagano, L., …, & Potenza, L. (2024). Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0306728

Vancouver

Bettelli F, Vallerini D, Lagreca I, Barozzi P, Riva G, Nasillo V, et al. Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0306728

BibTeX
@article{Bettelli2024,
  author = {Bettelli, Francesca and Vallerini, Daniela and Lagreca, Ivana and Barozzi, Patrizia and Riva, Giovanni and Nasillo, Vincenzo and Paolini, Ambra and D'Amico, Roberto and Forghieri, Fabio and Morselli, Monica and Pioli, Valeria and Gilioli, Andrea and Giusti, Davide and Messerotti, Andrea and Bresciani, Paola and Cuoghi, Angela and Colaci, Elisabetta and Marasca, Roberto and Pagano, Livio and Candoni, Anna and Maertens, Johan and Viale, Pierluigi and Mussini, Cristina and Manfredini, Rossella and Tagliafico, Enrico and Sarti, Mario and Trenti, Tommaso and Lewis, Russell and Comoli, Patrizia and Eccher, Albino and Luppi, Mario and Potenza, Leonardo},
  title = {Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306728}
}
Kostenlos starten →